Please assess the completion status of the following clinical trial:

Trial Title: Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 15 - 30 years~* Anorexia nervosa by psychiatric criteria~* Amenorrhea for at least 3 months~Exclusion Criteria:~* Receiving no medications known to affects bone metabolism~* No other chronic medical conditions

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Sugar Pill (Type: PLACEBO_COMPARATOR): Placebo (sugar pill); identical to treatment medication capsule
- DHEA + Hormone replacement therapy (estrogen/progestin) (Type: EXPERIMENTAL): Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (\> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).

Based on this trial design, predict the completion outcome and termination type (if applicable).